Arena Pharmaceuticals, Inc.

I-Lin Lin

Chen Wang Liaw

Karin Lehmann-Bruinsma

Ruoping Chen

Huong T Dang

Derek T Chalmers

James N Leonard

Dominic P Behan

Daniel Ortuño

Dominique Maciejewski-Lenior

The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors.

Nucleic acids encoding RUP3 and methods of using same

Nucleic acids encoding the GPCR, RUP3, and methods of use thereof

The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is known ('known GPCRs'), and most particularly to mutated (non-endogenous) versions of the known GPCRs for use, most preferably in screening assays for the direct identification of candidate compounds as inverse agonists, agonists and partial agonists.

Non-endogenous, constitutively activated known G protein-coupled receptors

The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor and to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.

Endogenous and non-endogenous versions of human G protein-coupled receptors

The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is known (&ldquo;known GPCRs&rdquo;), and most particularly to mutated (non-endogenous) versions of the known GPCRs for use, most preferably in screening assays for the direct identification of candidate compounds as inverse agonists, agonists and partial agonists.

Growing community of inventors

San Diego, CA, United States of America

I-Lin Lin